Physician profile
Michael E Politi
NPI 1669886636
$3,318.63
in general payments reported to CMS, 2019-2025
25 companies · $244 in 2025
The $244 reported for 2025 was less than what a typical Retina Specialist provider received nationally (typical 2025 total: $460).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $16.87 · 2020: $206 · 2021: $430 · 2022: $990 · 2023: $1,124 · 2024: $308 · 2025: $244.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,576 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,576.09 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $744.41 | 2022-2025 | Eylea Hd |
| Abbvie INC. | $692.13 | 2022-2025 | |
| Allergan, INC. | $249.57 | 2020-2022 | |
| Biotissue Holdings INC. | $208.04 | 2022-2024 | |
| Sun Pharmaceutical Industries INC. | $203.77 | 2021-2023 | Cequa |
| Mallinckrodt Hospital Products INC. | $182.03 | 2023 | Acthar |
| Alcon Vision LLC | $176.46 | 2021-2024 | Eysuvis, Simbrinza |
| Aerie Pharmaceuticals, INC. | $149.65 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $142.35 | 2020-2023 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $80.48 | 2021 | |
| Bausch & Lomb Americas INC. | $68.14 | 2022-2023 | Miebo |
| Sight Sciences, INC. | $46.83 | 2023 | Tearcare System |
| Harrow Eye, LLC | $44.32 | 2024 | Vevye |
| Dompe US, INC. | $43.93 | 2022-2023 | Oxervate |
| Carl Zeiss Meditec Ag | $38.80 | 2020 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Surgical Vision, INC. | $38.74 | 2021-2023 | Tecnis Iol |
| Akorn Operating Company LLC | $38.33 | 2021 | |
| Eyevance Pharmaceuticals LLC | $31.85 | 2020-2021 | |
| Oyster Point Pharma, INC. | $23.13 | 2022 | |
| Recordati_rare_diseases_inc. | $23.01 | 2023 | Cystadrops |
| Leadiant Biosciences, INC. | $21.12 | 2023 | Cystaran |
| Tarsus Pharmaceuticals, INC. | $19.95 | 2024 | Xdemvy |
| Thea Pharma INC. | $19.33 | 2022 | |
| Mallinckrodt Enterprises LLC | $16.87 | 2019 | |
| Kala Pharmaceuticals, INC. | $15.39 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Politi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.